Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: A controlled study in human chronic renal disease

Nephron

Volumn 75, Issue 3, 1997, Pages 286-294

  Samuelsson, O ^a   Attman, P O ^a   Knight Gibson, C ^a   Kron, B ^a   Larsson, R ^a   Mulec, H ^a   Weiss, L ^a   Alaupovic, P ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Apolipoproteins; Gemfibrozil; Lipoproteins; Renal insufficiency

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN; APOLIPOPROTEIN A; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CHOLESTEROL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUNSELING; DIET THERAPY; DYSLIPOPROTEINEMIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031046637     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000189551     Document Type: Article

References (36)

1. Attman P-O, Alaupovic P: Lipid and apolipo-prolcin profiles of uremic dyslipoproteincmia: Relation to renal function and dialysis. Nephron 1991;57:401-410.
2. Griitzmachcr P, März W, Peschkc B, Gross W, Schoeppe W: Lipoproteins and apolipoproteins during the progression of chronic renal disease. Nephron 1988;50:103-111.
3. Attman P-O, Samuclsson O, Alaupovic P: Lipid metabolism and renal failure. Am J Kidney Dis 1993;21:373-592.
4. Samuclsson O. Attman P-O. Knight-Gibson C, Krön B. Larsson R. Mulcc H. Weiss L. Alaupovic P: Lipoprotein abnormalities without hyperlipidemia in moderate renal insufficiency. Nephrol Dial Transplant 1994:9:1580-1585.
5. Attman P-O, Samuclsson O, Alaupovic P: Diagnosis and classification of dyslipidcmia in renal disease. Blood Purif 1996:14:49-57.
6. Chan TM. Cheng IKP. Tam SCF: Hyperlipidemia after renal transplantation: Treatment with gemfibrozil. Nephron 1994:67:317-321.
7. Ma KW. Greene EL, Raij L: Cardiovascular risk factors in chronic renal failure and hcino-dialvsis populations. Am J Kidnev Dis 1992; 19:505-513.
8. Keane WF, Kasiske BL. O’Donnell MP: Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis. Am J Nephrol 1988;8:261-271.
9. Massy ZA. Ma JZ, Louis TA, Kasiske B: Lipidlowering therapy in patients with renal disease. Kidney Int 1995;48:188-198.
10. Todd PA. Ward A: Gemfibrozil: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidemia. Drugs 1988;36:314-339.
11. Friedcwald WT. Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
12. Alaupovic P, Hodis HN. Knight-Gibson C, Mack WJ, LaBree L, Cashin-Hemphill L, Corder CN, Kramsch DM. Blankenhom DH: Effects of lovastatin on apoA-and apoB-con-taining lipoprotein families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS). Arte-rioscler Thromb 1994; 14:1906-1914.
13. Alaupovic P: Apolipoprotein composition as the basis for classifying plasma lipoproteins. Characterizations of Apo A-and Apo B-con-taining lipoprotein families. Prog Lipid Res 1991;30:105-138.
14. Jagenburg R, Attman P-O, Aurell M. Bucht H: Determination of glomerular filtration rate in advanced renal insufficiency. Scand J Urol Nephrol 1978;12:133-137.
15. Lacour B. Roullet J-B, Beyne P, Kreis H. Thc-venin M. Driieke T: Comparison of several ath-erogenicity indices by the analysis of serum lipoprotein composition in patients with chronic renal failure with or without hemodialysis, and in renal transplant patients. J Clin Chem Clin Biochem 1985;23:805-810.
16. Bcrgcsio F. Monzani G, Ciuti R, Serruto A, Benucci A, Frizzi V. Salvadori M: Lipids and apolipoproteins change during progression of chronic renal failure. Clin Nephrol 1992:38: 264-270.
17. Wight JP, Salzano S. Brown CB, El Nahas AM: Natural history of chronic renal failure: A reappraisal. Nephrol Dial Transplant 1992:7:379-383.
18. McCosh EJ, Solangi K, Rivers JM, Goodman A: Hypertriglyceridemia in patients with chronic renal insufficiency. Am J Clin Nutr 1975;28:1036-1043.
19. Sakurai T, Oka T, Hasegawa H, lgaki N. Miki S, Goto T: Comparison of lipids, apoproteins and associated enzyme activities between diabetic and nondiabetic end-stage renal disease. Nephron 1992;61:409-414.
20. Chan MK, Persaud J, Varghese Z, Moorhead JF: Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients. Kidney Int 1984;25:812-818.
21. Bagdade JD. Yce E, Wilson DE, Shafir E: Hyperlipidemia in renal failure: Studies of plasma lipoproteins, hepatic triglyceride production and tissue lipoprotein lipase in a chronically uremic rat mode. J Lab Clin Med 1978:91:176-186.
22. Goldberg AP, Applcbaum-Bowden DM. Bier-man EL, Hazzard WR, Haas LB, Sherrard DJ. Brunzell JD, Huttunen JK, Ehnholm C, Nikki-la EA: Increase in lipoprotein lipase during clo-fibratc treatment of hypertriglyceridemia in patients on hemodialysis. N Engl J Med 1979; 301:1073-1076.
23. Attman P-O, Gustafson A. Alaupovic P, Wang C-S: Effect of protein-reduced diet on plasma lipids, apolipoproteins and lipolytic activities in patients with chronic renal failure. Am J Nephrol 1984;4:92-98.
24. Pasternack A, Vânttinen T, Solakivi T, Kuusi T. KorteT: Normalization oflipoprotein lipase and hepatic lipase by gemfibrozil results in correction oflipoprotein abnormalities in chronic renal failure. Clin Nephrol 1987;27:163-168.
25. Tikkanen MJ: Fibric acid derivatives. Curr Opin Lipidol 1992;3:29-33.
26. Groggel GC, Cheung AK. Ellis-Benigni K. Wilson DE: Treatment of nephrotic hyperlipoproteinemia with gemfibrozil. Kidney Int 1989:36: 266-271.
27. Eisalo A. Manninen V, Malkônen M, Kuhl-biack B: Hypolipidemic action of gemfibrozil in adult nephrotics. Proc R Soc Med 1976:69 (suppl 2):47-48
28. Williams AJ. Bakker F. Walls J: The short term effects of bezafibratc on the hypertriglyceridemia of moderate to severe uremia. Br J Clin Pharmacol 1984:18:361-367.
29. Norbeck HE, Andcrsson P: Treatment of uremic hypertriglyceridemia with bezafibratc. Atherosclerosis 1982:44:125-136.
30. Chan MK: Gemfibrozil improves abnormalities of lipid metabolism in patients on continuous ambulatory peritoneal dialysis: The role of postheparin lipases in the metabolism of high-density lipoprotein subtractions. Metabolism 1989:38:939-945.
31. Alaupovic P. Knight-Gibson C. Bryant S. Lars-son R. Mulcc H. Weiss L. Attman P-O, Samu-elsson O: Dyslipoprotcinemia of chronic renal failure is characterized by decreased levels of lipoprotein A-LA-1I and increased levels of apoC-III-comaining triglyceride-rich lipoproteins (abstract). 62nd Congr Eur Atherosclerosis Soc, Jerusalem, Sept 5-9, 1993.
32. Attman P-O. Tavella M. Knight-Gibson C, Samuelsson O. Alaupovic P: Apolipoprotein B-containing lipoprotein particles in progressive renal insufficiency: in Guarnieri G, Panzetta G. Toigo G (eds): Metabolic and Nutritional Abnormalities in Kidney Disease. Scientific Meeting of the European Study Group for Conservative Management of Chronic Renal Failure, Triest. 1991. Contrib Nephrol. Basel. Kargcr, 1992. vol 98, pp 11-19.
33. Hodis HN. Mack WJ. Azen SP, Alaupovic P, Pogoda JM. LaBrec L, Hemphill LC, Kramsch DM. Blankenhom DH: Triglyceride-and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994:90:42-49.
34. Alaupovic P, Knight-Gibson C. Hodis HN. Mack WJ. Cashin-Hemphill L, Blankenhom DH: Effect of apoB-containing lipoprotein particles on the progression of atherosclerotic lesions in the Monitored Atherosclerosis Study (MARS). Atherosclerosis 1994:109:154.
35. Frick MH. Elo O. Haapa K. Hcinonen OP. Heinsalmi P, Helo P, Huttunnen JK. Kaitan-iemi P, Koskinen P. Manninen V. Mâenpaa H. Mâlkonen M. Mânttâri M. Norola S, Pasternack A. Pikkarainen J. Romo M. Sjôblom T. Nikkilâ EA: The Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237-1245.
36. Hodis HN, Mack WJ, LaBree L, Selzcr RH, Liu C-R. Liu C-H. Alaupovic P, Hclcnann K-F, Azen SP: Reduction in carotid arterial wall intima-media thickness using lovastatin and dietary therapy. A randomized, controlled clinical trial. Ann Intern Med 1996;124:548-556.